$AVXL
ANAVEX LIFE SCIENCES CORP.

2023 Q1 Form 10-Q Financial Statement

#000173112223000152 Filed on February 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.883M $3.317M $3.067M
YoY Change -1.12% 8.15% 108.64%
% of Gross Profit
Research & Development $11.31M $12.07M $8.656M
YoY Change 31.4% 39.4% 9.16%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $14.19M $15.38M $11.72M
YoY Change 23.17% 31.22% 24.72%
Operating Profit -$14.19M -$15.38M -$11.72M
YoY Change 23.17% 31.22%
Interest Expense $382.2K $1.634M $60.27K
YoY Change 38.36% 2610.47% -81.74%
% of Operating Profit
Other Income/Expense, Net $1.132M $2.392M $810.7K
YoY Change 35.47% 195.07% -36.16%
Pretax Income -$13.06M -$12.99M -$10.85M
YoY Change 25.45% 19.71% 39.13%
Income Tax $50.00K -$20.05K $29.98K
% Of Pretax Income
Net Earnings -$13.11M -$12.97M -$10.88M
YoY Change 25.57% 19.2% 38.45%
Net Earnings / Revenue
Basic Earnings Per Share -$0.17 -$0.17
Diluted Earnings Per Share -$0.17 -$0.17 -$143.2K
COMMON SHARES
Basic Shares Outstanding 78.03M shares 77.96M shares
Diluted Shares Outstanding 78.30M shares 77.98M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $153.5M $143.6M $151.1M
YoY Change 0.08% -4.98% 219.14%
Cash & Equivalents $153.5M $143.6M $151.1M
Short-Term Investments
Other Short-Term Assets $981.8K $655.6K $377.9K
YoY Change 111.31% 73.51% -5.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $159.2M $148.4M $156.9M
YoY Change -0.68% -5.43% 188.78%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$3.00 $2.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $159.2M $148.4M $156.9M
Total Long-Term Assets -$3.00 $2.00 $0.00
Total Assets $159.2M $148.4M $156.9M
YoY Change -0.68% -5.43% 188.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.282M $5.288M $4.635M
YoY Change 138.68% 14.1% 9.83%
Accrued Expenses $6.823M $7.043M $5.450M
YoY Change 36.58% 29.23% 42.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.02M $13.25M $10.53M
YoY Change 73.72% 25.83% 31.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $14.02M $13.25M $10.53M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $14.02M $13.25M $10.53M
YoY Change 73.72% 25.83% 31.12%
SHAREHOLDERS EQUITY
Retained Earnings -$271.6M -$258.5M
YoY Change
Common Stock $416.8M $393.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $145.2M $135.1M $146.4M
YoY Change
Total Liabilities & Shareholders Equity $159.2M $148.4M $156.9M
YoY Change -0.68% -5.43% 188.78%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2021 Q4
OPERATING ACTIVITIES
Net Income -$13.11M -$12.97M -$10.88M
YoY Change 25.57% 19.2% 38.45%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$8.489M -$5.794M -$3.501M
YoY Change -11.94% 65.5% -55.52%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.686M
YoY Change -89.76%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 18.33M $258.2K 2.540M
YoY Change 54.9% -89.83% -90.22%
NET CHANGE
Cash From Operating Activities -8.489M -$5.794M -3.501M
Cash From Investing Activities
Cash From Financing Activities 18.33M $258.2K 2.540M
Net Change In Cash 9.845M -$5.536M -961.4K
YoY Change 348.28% 475.83% -105.31%
FREE CASH FLOW
Cash From Operating Activities -$8.489M -$5.794M -$3.501M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001314052
CY2022Q4 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q4 avxl Non Operating Income From Grants
NonOperatingIncomeFromGrants
usd
CY2021Q4 avxl Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
usd
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2022Q4 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
usd
CY2021Q4 avxl Cash Paid For State And Local Minimum Income Taxes
CashPaidForStateAndLocalMinimumIncomeTaxes
usd
CY2022Q4 dei Document Type
DocumentType
10-Q
CY2022Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q4 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q4 dei Entity File Number
EntityFileNumber
001-37606
CY2022Q4 dei Entity Registrant Name
EntityRegistrantName
ANAVEX LIFE SCIENCES CORP.
CY2022Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0608404
CY2022Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
630 5th Avenue
CY2022Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
20th Floor
CY2022Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022Q4 dei Entity Address Country
EntityAddressCountry
US
CY2022Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10111
CY2022Q4 dei City Area Code
CityAreaCode
844
CY2022Q4 dei Local Phone Number
LocalPhoneNumber
689-3939
CY2022Q4 dei Security12b Title
Security12bTitle
Common Stock Par Value $0.001
CY2022Q4 dei Trading Symbol
TradingSymbol
AVXL
CY2022Q4 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q4 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q4 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q4 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
78032135 shares
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
143621848 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149157861 usd
CY2022Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
4094431 usd
CY2022Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
3192580 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
655643 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
354162 usd
CY2022Q4 us-gaap Assets
Assets
148371922 usd
CY2022Q3 us-gaap Assets
Assets
152704603 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5288261 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3824777 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7042822 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5944953 usd
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
916763 usd
CY2022Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
443831 usd
CY2022Q4 us-gaap Liabilities
Liabilities
13247846 usd
CY2022Q3 us-gaap Liabilities
Liabilities
10213561 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78032135 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78032135 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77942815 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77942815 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
78033 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
77944 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
393581544 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
387976881 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-258535501 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245563783 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
135124076 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
142491042 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
148371922 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
152704603 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3317036 usd
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3066951 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12066919 usd
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8656439 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
15383955 usd
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
11723390 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-15383955 usd
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-11723390 usd
CY2022Q4 avxl Non Operating Income From Grants
NonOperatingIncomeFromGrants
25000 usd
CY2022Q4 avxl Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
733590 usd
CY2021Q4 avxl Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
810730 usd
CY2022Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1267618 usd
CY2021Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4910 usd
CY2022Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
365983 usd
CY2021Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
55363 usd
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2392191 usd
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
871003 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12991764 usd
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10852387 usd
CY2022Q4 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-20046 usd
CY2021Q4 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
29980 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-12971718 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-10882367 usd
CY2022Q4 avxl Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.17
CY2021Q4 avxl Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.14
CY2022Q4 avxl Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
77977112
CY2021Q4 avxl Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
75997738
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
142491042 usd
CY2022Q4 avxl Shares Issued Pursuant To Exercise Of Stock Options
SharesIssuedPursuantToExerciseOfStockOptions
258244 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5346508 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-12971718 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
135124076 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
150818104 usd
CY2021Q4 avxl Shares Issued Pursuant To Exercise Of Stock Options
SharesIssuedPursuantToExerciseOfStockOptions
373497 usd
CY2021Q4 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2149701 usd
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3908771 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-10882367 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
146367706 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-12971718 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-10882367 usd
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
5346508 usd
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
3908771 usd
CY2022Q4 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
901851 usd
CY2021Q4 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-3764678 usd
CY2022Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
301481 usd
CY2021Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
22311 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1463484 usd
CY2021Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-104992 usd
CY2022Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1097869 usd
CY2021Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-164734 usd
CY2022Q4 avxl Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
472932 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5794257 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3500955 usd
CY2021Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2312785 usd
CY2021Q4 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
146717 usd
CY2022Q4 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
258244 usd
CY2021Q4 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
373497 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
258244 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2539565 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5536013 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-961390 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
149157861 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
152107745 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143621848 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
151146355 usd
CY2022Q4 avxl Cash Paid For State And Local Minimum Income Taxes
CashPaidForStateAndLocalMinimumIncomeTaxes
50077 usd
CY2022Q4 us-gaap Basis Of Accounting
BasisOfAccounting
<p id="xdx_805_eus-gaap--BasisOfAccounting_zbDwoEqw09j3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 <span id="xdx_821_zqATGLBhz5C1">Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zUQdtJi6fuVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i><span id="xdx_86E_zOC3uQ5iyg6a">Basis of Presentation</span> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. Accordingly, certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information presented not misleading.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2022 was derived from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended September 30, 2022 filed with the SEC on November 28, 2022. The Company follows the same accounting policies in the preparation of interim reports.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the three months ended December 31, 2022 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_ecustom--LliquidityPolicyTextBlock_zkX9GKxjPX1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zM92AZ1bBeL9">Liquidity</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company’s potential drug compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital position will be sufficient to meet the Company’s working capital requirements beyond the next 12 months after the date that these interim condensed consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials are uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company’s expenditures will vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company’s research and development programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future clinical trials.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--UseOfEstimates_zAlWL6YlnfB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_868_zWRNrnlTlPVf">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84E_ecustom--CoronavirusDisease2019COVID19PolicyTextBlock_zHJrC2UOD7S2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_866_zCUIR1Nn6Pfj">Coronavirus Disease 2019 (COVID-19)</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The global pandemic resulting from the disease known as COVID-19, caused by a novel strain of coronavirus, did not have a material impact on the Company’s result of operations or financial condition for the quarter ended December 31, 2022. However, the future course of the pandemic could have adverse effects in the U.S and global economies and thus negatively impact our business and financial results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zhVa66jQ8Wrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zVrH6HBuajQ8">Principles of Consolidation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (“Anavex Australia”), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>  </i></b></p> <p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbCYyGFjyKQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_865_zdQgm5cfTk02">Fair Value Measurements</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2022 and September 30, 2022, the Company did not have any Level 3 assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zldoy5WGjNTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_866_z4OE5XqndfY2">Basic and Diluted Loss per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022 loss per share excludes <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20221231_pdd" title="Loss per share for potentially dilutive common shares">13,525,296</span> (December 31, 2021: <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20211231_zbRpyyYJm8Vj" title="Loss per share for potentially dilutive common shares">11,403,769</span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQkq8c6YE9S9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_869_zqtvQrQwJJXk">Recently Adopted Accounting Pronouncements</span> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance” (“ASU 2021-10”). ASU 2021-10 increases the disclosure requirements for annual reporting periods relating to material government assistance transactions on the entity’s financial statements and any significant terms and conditions of the agreements including commitments and contingencies. The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company receives from the Australian Tax Office (“ATO”) for its clinical trials in Australia.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
CY2022Q4 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zAlWL6YlnfB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_868_zWRNrnlTlPVf">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2022Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13525296 shares
CY2021Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11403769 shares
CY2022Q4 avxl Non Operating Income From Grant
NonOperatingIncomeFromGrant
25000 usd
CY2021Q4 avxl Non Operating Income From Grant
NonOperatingIncomeFromGrant
0 usd
CY2022Q4 avxl Deferred Grant Income
DeferredGrantIncome
916763 usd
CY2022Q3 avxl Deferred Grant Income
DeferredGrantIncome
443831 usd
CY2022Q4 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
733590 usd
CY2021Q4 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
810730 usd
CY2022Q4 avxl Accrued Clinical Site And Patient Visits Costs
AccruedClinicalSiteAndPatientVisitsCosts
2212464 usd
CY2022Q3 avxl Accrued Clinical Site And Patient Visits Costs
AccruedClinicalSiteAndPatientVisitsCosts
2031105 usd
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1249205 usd
CY2022Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1297337 usd
CY2022Q4 avxl Fixed Contract Accruals
FixedContractAccruals
1076630 usd
CY2022Q3 avxl Fixed Contract Accruals
FixedContractAccruals
417414 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2504523 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2199097 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7042822 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5944953 usd
CY2022Q4 avxl Sales Of Agreement Amount
SalesOfAgreementAmount
142407882 usd
CY2022Q3 avxl Sales Of Agreement Amount
SalesOfAgreementAmount
142407882 usd
CY2022Q4 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
30070 usd
CY2021Q4 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
4845 usd
CY2022Q4 us-gaap Pension Contributions
PensionContributions
43646 usd
CY2021Q4 us-gaap Pension Contributions
PensionContributions
22682 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
160000 shares
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
160000 shares
CY2022Q4 avxl Warrants Outstanding Weighted Average Exercise
WarrantsOutstandingWeightedAverageExercise
3.72
CY2022Q3 avxl Warrants Outstanding Weighted Average Exercise
WarrantsOutstandingWeightedAverageExercise
3.72
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
160000 shares
CY2022Q4 avxl Option Issued
OptionIssued
2378000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
4.40
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
2.85
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M4D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M24D
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P4Y9M29D
CY2022 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P5Y1M6D
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5346508 usd
CY2021Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3908771 usd
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5346508 usd
CY2021Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3908771 usd
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
16340941 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0407 pure
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0137 pure
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y11M23D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8401 pure
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9679 pure
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2022Q4 us-gaap Significant Purchase Commitment Description
SignificantPurchaseCommitmentDescription
the Company entered into a Purchase Agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), whereby the Company has the right, in its sole discretion, to sell to LPC up to $150,000,000 in value of shares of the Company’s common stock from time to time over a 36-month period pursuant to the terms of the Purchase Agreement.

Files In Submission

Name View Source Status
0001731122-23-000152-index-headers.html Edgar Link pending
0001731122-23-000152-index.html Edgar Link pending
0001731122-23-000152.txt Edgar Link pending
0001731122-23-000152-xbrl.zip Edgar Link pending
avxl-20221231.xsd Edgar Link pending
e4385_10-q.htm Edgar Link pending
e4385_ex10-1.htm Edgar Link pending
e4385_ex31-1.htm Edgar Link pending
e4385_ex31-2.htm Edgar Link pending
e4385_ex32-1.htm Edgar Link pending
e4385_ex4-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
avxl-20221231_def.xml Edgar Link unprocessable
avxl-20221231_pre.xml Edgar Link unprocessable
avxl-20221231_cal.xml Edgar Link unprocessable
avxl-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
e4385_10-q_htm.xml Edgar Link completed